Mov Disord Vol 31, Suppl 2 Archives - Page 44 of 207 - MDS Abstracts

2016 International Congress
Relationship of MDS-UPDRS non-motor symptoms to cognitive functioning in patients with Parkinson’s disease
B.A. Bernard, D. Carns, G.T. Stebbins, J.G. Goldman, C.G. Goetz (Chicago, IL, USA)
Objective: To evaluate the relationship among individual items from the MDS-UPDRS Part I and measures of cognitive functioning in patients with PD. Background: Non-motor symptoms…
2016 International Congress
Dopaminergic drug management in Parkinson’s disease: Gait and language function show correlation during treatment
H. Murakami, A. Futamura, T. Kuroda, S. Ishigaki, M. Kezuka, K. Ono, M. Kawamura (Tokyo, Japan)
Objective: We examined the effects of dopaminergic medication adjustment on cognitive function in Parkinson's disease (PD) patients without apparent dementia (Mini-Mental State Examination score of…
2016 International Congress
Investigating the relationship between reaction time and cognition in Parkinson’s disease
J. Cosgrove, C. Picardi, S.L. Smith, S. Jamieson, J.E. Alty (Leeds, United Kingdom)
Objective: To test the hypothesis that simple reaction time (SRT) is associated with global cognition in Parkinson's disease (PD) after controlling for motor function. Background:…
2016 International Congress
A technological solution for monitoring Parkinson’s disease: A patient-based perspective on necessity, usability and acceptability
S. Couth, E. Poliakoff, J. Vega, C. Jay, S. Harper, R. Almutiry, T.F. Cootes, A.M. Ramsay, S.A. Kotz (Manchester, United Kingdom)
Objective: The objectives of this study were twofold. First, to determine the feasibility of monitoring changes in how people with Parkinson's feel, think, and behave…
2016 International Congress
The effect of dopamine on global versus specific inhibitory control in Parkinson’s disease
D. Kuebler, H. Schroll, R. Eva, A. Diepold, C. Meyer, A. Kuhn (Berlin, Germany)
Objective: To evaluate the effect of dopaminergic medication on inhibitory control using a novel go/no-go task in Parkinson's disease (PD). Global cognition and motor examination…
2016 International Congress
Apolipoprotein E genotypes in Brazilian patients with Parkinson’s disease and their correlation with cognitive performance assessed by MoCA
M.M.C.M. Brito, R.S.J. Silva, V. Tumas, I.F. Mata, C.Z. Zabetian (Ribeirão Preto, Brazil)
Objective: Analysing the relationship between the polymorphisms of ApoE gene and cognitive performance of patients with Parkinson's disease. Background: Cognitive impairment is a common clinical…
2016 International Congress
Illusional perception in Parkinson’s disease
C. Ding, C. Palmer, J. Hohwy, G. Youssef, B. Paton, N. Tsuchiya, J. Stout, D. Thyagarajan (Clayton, Australia)
Objective: To investigate (a) whether a susceptibility to illusional perceptions is intrinsic to Parkinson's disease even before the onset of hallucinations or cognitive impairment and…
2016 International Congress
Technology use and impulse control disorders (ICDs) in patients with Parkinson’s disease (PD)
E.A. Byrd, C.M. Tanner, C.A. Racine, N.B. Galifianakis (San Francisco, CA, USA)
Objective: To ascertain the prevalence of problematic technology use (Technology-related ICDs, Tech-ICDs) in patients with PD. Background: ICDs are a known complication of PD drugs…
2016 International Congress
Factors related to psychotic symptoms in patients with Parkinson’s disease
B. Tserensodnom (Ulaanbaatar, Mongolia)
Objective: The aim of this study was to compare clinical characteristics in Parkinson's disease (PD) with psychosis (PDP) versus PD without psychosis (PDnP) and evaluate…
2016 International Congress
Choreoathetosis associated with cervical dystonia as clinical presentation of thyrotoxicosis: A rare condition
S.C.B. Casagrande, S.M.C.d.A. e Silva (São Paulo, Brazil)
Objective: To describe the first report of Cervical Dystonia and Choreoatetosis associated in the same patient with hyperthyroidism (thyrotoxicosis). Background: Thyroid Disease is related with…